Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Spevigo® (spesolimab-sbzo) – New orphan drug approval
September 1, 2022 - Boehringer Ingelheim announced the FDA approval of Spevigo (spesolimab-sbzo), for the treatment of generalized pustular psoriasis (GPP) flares in adults.
